CR20230566A - Derivados de triazina y su uso en el tratamiento del cáncer - Google Patents

Derivados de triazina y su uso en el tratamiento del cáncer

Info

Publication number
CR20230566A
CR20230566A CR20230566A CR20230566A CR20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A CR 20230566 A CR20230566 A CR 20230566A
Authority
CR
Costa Rica
Prior art keywords
sup
cancer
treatment
triazine derivatives
compounds
Prior art date
Application number
CR20230566A
Other languages
English (en)
Inventor
Andreas Michael Tosstorff
Georg Jaeschke
Stefanie Katharina Mesch
Christian Schnider
Sandra Steiner
Lea Aurelie Bouche
Wolfgang Guba
Angélique Patiny-Adam
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230566A publication Critical patent/CR20230566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general Ib, en donde R1, R2, R3, R4, R5 y Z son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
CR20230566A 2021-06-04 2022-06-02 Derivados de triazina y su uso en el tratamiento del cáncer CR20230566A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21177660 2021-06-04
EP21188639 2021-07-30
EP21215875 2021-12-20
PCT/EP2022/064995 WO2022253936A1 (en) 2021-06-04 2022-06-02 Triazine derivatives and their use in the treatment of cancer.

Publications (1)

Publication Number Publication Date
CR20230566A true CR20230566A (es) 2024-01-22

Family

ID=82115763

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230566A CR20230566A (es) 2021-06-04 2022-06-02 Derivados de triazina y su uso en el tratamiento del cáncer

Country Status (16)

Country Link
US (1) US20240132471A1 (es)
EP (1) EP4347571A1 (es)
JP (1) JP2024522494A (es)
KR (1) KR20240019083A (es)
AR (1) AR126053A1 (es)
AU (1) AU2022287224A1 (es)
BR (1) BR112023025318A2 (es)
CA (1) CA3216026A1 (es)
CL (1) CL2023003491A1 (es)
CO (1) CO2023016212A2 (es)
CR (1) CR20230566A (es)
IL (1) IL307201A (es)
MX (1) MX2023013998A (es)
PE (1) PE20240928A1 (es)
TW (1) TW202313577A (es)
WO (1) WO2022253936A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
AU2023205375A1 (en) * 2022-01-07 2024-07-18 Transthera Sciences (Nanjing) , Inc. Nlrp3 inflammasome inhibitor and uses thereof
WO2024017924A1 (en) * 2022-07-21 2024-01-25 F. Hoffmann-La Roche Ag Nlrp3 inhibitors
CN117986258A (zh) * 2022-11-04 2024-05-07 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
WO2024121086A1 (en) * 2022-12-07 2024-06-13 F. Hoffmann-La Roche Ag Novel compounds as modulators of nlrp3 inhibition
WO2024193541A1 (en) * 2023-03-20 2024-09-26 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
WO2024193703A1 (zh) * 2023-03-23 2024-09-26 成都赜灵生物医药科技有限公司 三嗪类化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3920917A4 (en) * 2019-02-04 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021150574A1 (en) 2020-01-22 2021-07-29 Genentech, Inc. Sulfonimidamide compounds as nlrp3 modulators

Also Published As

Publication number Publication date
IL307201A (en) 2023-11-01
CO2023016212A2 (es) 2023-12-11
MX2023013998A (es) 2023-12-11
AU2022287224A1 (en) 2023-09-21
CL2023003491A1 (es) 2024-05-24
AR126053A1 (es) 2023-09-06
BR112023025318A2 (pt) 2024-02-27
EP4347571A1 (en) 2024-04-10
KR20240019083A (ko) 2024-02-14
WO2022253936A1 (en) 2022-12-08
CA3216026A1 (en) 2022-12-08
PE20240928A1 (es) 2024-04-30
JP2024522494A (ja) 2024-06-21
US20240132471A1 (en) 2024-04-25
TW202313577A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
TW200745004A (en) Novel compounds, their preparation and use
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
TW200630374A (en) Thiazolyldihydroindazoles
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
MX2023012907A (es) Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3).
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
EP4233865A3 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
WO2023107574A3 (en) Lipid-based compositions and methods thereof
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
MX2022011646A (es) Celulas t v delta1+ para el tratamiento de neoplasias mieloides.
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
MX2021009206A (es) Terapias contra el cancer.
CL2022003400A1 (es) Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del síndrome de tourette
MXPA03005374A (es) Carbazoles antitumorales.
WO2023049808A3 (en) Small molecule inhibitors of tead-yap